There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.

The new trading week kicks off with Amylin Pharmaceuticals (Nasdaq: AMLN) reporting its quarterly results. The FDA just cleared Amylin's new diabetes treatment, so the past quarter may not be as important as what the biotech has to say about its future earnings power.

Glu Mobile (Nasdaq: GLUU) is one of the many companies reporting on Tuesday. Analysts see the smartphone-app maker posting a widening deficit, but investors accept that, given the long-term potential of mobile gaming.

Akamai (Nasdaq: AKAM) checks in on Wednesday. The leading content-delivery network helps websites serve up fast and secure website pages and digital files. This is a cutthroat business, but Akamai's scale and its knack for snapping up the occasional disruptor has helped keep the company profitable and growing.

Facebook hype is in the air, but what about the social-networking websites that are already trading on the open market? LinkedIn (Nasdaq: LNKD) went public last May. It steps up for its quarterly report -- and possible a reflection on Facebook -- when it reports on Thursday.

The final trading day of the week features a company that makes the trading possible. New York Stock Exchange operator NYSE Euronext (NYSE: NYX) steps up with what analysts think will be slightly improved profitability.

If you like to stay on top of what happens next -- and I'm guessing you do, because you're reading this article -- how about checking out Motley Fool's top stock for 2012? It's a free report, but only for a limited time, so check it out now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.